Senzime AB (publ) SNZZF
Set alert
0.24 USD 0.00 0.00%
At close · Nov 2
0.2609 Day range 0.2609
0.2352 52-week range 0.65
- YTD
- -56.61%
- 1 year
- -63.82%
- Open
- 0.2609
- Prev close
- 0.2352
- Mkt cap
- 46.32M
- Vol
- 2.50K
- Avg vol
- 9.77K
- EPS
- -0.07
- P/E
- 0.00
More statistics
- Low
- 0.2609
- High
- 0.2609
3M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 13, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 3, 2026 | 2 months ago |
| RSI: Oversold | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 17, 2026 | 2 months ago |
News
- Senzime AB (publ) (SNZZF) Q3 2026 Earnings Call Transcript
- Senzime AB (publ) (SNZZF) Q3 2026 Earnings Call Prepared Remarks Transcript
- New Scientific Evidence Presented at ANESTHESIOLOGY 2026 Strengthens the Case for Senzime's TetraGraph and Quantitative Neuromuscular Monitoring
- Senzime Launches Industry-First Predictive Neuromuscular Monitoring Technology
- Senzime Reaffirms Its Target of Reaching Positive Cash Flow Within Q4 2026
- Senzime AB (publ) (SNZZF) Discusses Market Update, Philips Partnership, OEM Business Insights and Financing Package Transcript
- Senzime Strengthens Financing to Support Strategic OEM Expansion and Path to Profitability
- Senzime Secures Additional Major US Hospital Network Contract, Expanding Adoption of its Next-generation Neuromuscular Monitoring Technology
- Senzime Awarded Exclusive 5-Year National Supply Contract with U.S. Veterans Affairs Through Its Partner TrillaMed
- Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on SNZZF — it syncs with the Stock Master app.